United Kingdom

Welcome to the UK page of the ESCP web site

This page contains details about Colorectal practice and research in the UK, along with details of our National Association - The Association of Coloproctology of Great Britain and Ireland (www.acpgbi.org.uk). I hope you will find this useful and informative. If any member of the ESCP wishes to contact me on any matter, please do not hesitate to contact me via email at peter.dawson@imperial.nhs.uk. I look forward to hearing from you.

Please note my successor from September 2011 will be Mr Paris Tekkis who works at the Royal Marsden and Chelsea and Westminster Hospitals , London

Best wishes
Peter Dawson

Population: 61,000,000
ESCP Members: 120
Colorectal Surgeons: 650
ESCP Representative Name: Peter Dawson ( Mr Paris Tekkis from September 2011)
National Examination: Intercollegiate Fellowship Examination (Colorectal) FRCS Gen Surg

Achievements: 

Recent achievements in the UK include:

  • The National Training Programme (NTP) in laparoscopic colorectal surgery is expanding its base of Consultant trainees across the country.
  • Preliminary results from the ACT II trial suggest that allthough CisPlatinum during chemoradiation and maintainance chemotherapy are feasible to deliver, neither approach leads to an improved significant difference in outcome for patients.
  • Early results from the UK Pouch registry have been published in Colorectal Disease
  • The Department of Health has recently launched an Enhanced Recovery Programme to agree principles of care across multiple specialty pathways and to sustain this practice across the NHS
  • A National training course in the managment of low rectal cancer
  • Immersion courses for laparoscopic colorectal trainees www.pelicancourses.org
     

Current Research: 

FOxTROT: Fluoropyrimidine, Oxaliplatin and Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable colon cancer. Early results look promising with downstaging of tumours.

ACT II: A Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients with Anal Cancer
QUASAR 2: Comparing capecitabine, against capecitabine + Avastin® (bevacizumab) with the expectation that adding bevacizumab to capecitabine may have the potential for improved relapse free and overall survival compared to capecitabine alone. This study now closed.
SCOT: Short Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3 Groups
COIN-B: (COIN-Biological) is an open-label, multi-centre, randomised Phase II trial assessing how cetuximab might be best added to chemotherapy, and about the benefits of intermittent chemotherapy in first line treatment of metastatic colorectal cancer.Results awaited.
PICCOLO: A randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan (Ir) versus irinotecan plus panitumumab (PAN) and versus irinotecan plus ciclosporin (Cs). The primary endpoints are Ir vs IrCs comparison: Proportion of patients progression-free 12 weeks after randomisation and Ir vs IrPan comparison (patients not previously receiving cetuximab): Overall survival (OS) from randomisation.
EPOC: Peri-operative chemotherapy in patients with resectable colorectal liver metastases - does the addition of an anti-EGF receptor antibody improve progression free survival?
CR07:  compares two differentr adiotherapy policies when combined with mesorectal excision. This is a randomised trial to assess whether local recurrence-free rates and quality of life are optimised by giving all patients short course pre-operative radiotherapy, or to give post-operative chemo-radiotherapy only to those at high risk of recurrence.
CHRONICLE: Chemotherapy or no chemotherapy in clear margins after neoadjuvant chemoradiation in locally advanced rectal cancer: A randomised phase III trial of control vs capecitabine plus oxaliplatin.
FOCUS3: This is a study using Ki- Ras and TOPO 1 status to determine subsequent therapy
FACS: A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent.
XERXES: Examining the role of Early Neoadjuvant and Synchronous Erbitux in Preoperative Chemo-Radiotherapy using Xeloda followed by Excisional Surgery.
PROSPER:(PROlapse Surgery: PErineal or Rectopexy) The trial is designed to recruit and randomise 1,000 patients, commenced in 2004 and separated short-term perioperative results and functional outcomes by comparing two main abdominal operations, abdominal rectopexy and resection rectopexy, with two principal perineal procedures, the Delorme mucosectomy and the Altemeier perineal rectosigmoidectomy. It will assess basic demography, risk factors, standardised defecatory function and quality of life.
CReST: A UK prospective multicentre randomized trial evaluating the role of endoluminal stenting in the acute management of obstructing colorectal cancer.
 
FIAT 500: Assessing the use of a collagen fistula plug for fistula in ano.

Future Plans: 

Future courses Spring 2011

February 17th & 18th 2011  
Low Rectal Cancer Symposium
*50% bursaries are available – apply now*
Convenors: Mr Brendan Moran, Prof. R J Heald
A two day meeting with eminent multidisciplinary faculty and live rectal surgery.
Cost: £595 for consultants; £495 for SpRs

March 2nd 2011
Steps of TME Masterclass
*50% bursaries are available – apply now*
Convenor: Prof. R J Heald
A 1-day course with Professor Bill Heald, the father of TME, going through the surgical steps for rectal cancer.  This course is suitable for Specialist Registrars or newly appointed consultants. 
Cost: £195.00.
www.pelicancourses.org

March 9th 2011
LOREC Workshop
(Part of the national development programme funded by NCAT)
Convenor: Mr Brendan Moran
A 1-day workshop discussing the assessment and management of low rectal cancers.

March 23rd - 25th 2011
Colorectal Diseases M25 Course
Convenors: Mr Muti Abulafi, Mr John Stebbing
An intensive three-day course designed to provide an in-depth review of all aspects of colorectal disease.
Cost: £400.00 (without accommodation)
www.pelicancourses.org

Affiliates